Non-Human Primate Early Stage Investigator Scholars

This program is no longer active.

2009-2011 | 2010-2012 | 2011-2013


2011-2013 Scholars

Keith Reeves, Ph.D.
New England Primate Research Center

Title: "Role of mucosal NK cells in control and pathogenesis of lentivirus infections"

Description: Lentivirus infections are characterized by a rapid loss of mucosal CD4+ T cells and breakdown of the gut mucosa associated with subsequent chronic immune activation. Read more >


Shaunna (Xiaoying) Shen, D.V.M., Ph.D.
Shaunna (Xiaoying) Shen, D.V.M., Ph.D.
Department of Surgery and Duke Human Vaccine Institute

Title: "Antibody Measurements Indicative of Protective
Antibodies for HIV-1"

Description: The results of the RV144 efficacy trial raise the question of whether antibody responses other than traditional neutralizing antibody responses could prevent HIV-1 acquisition. Read more >


Carolina Herrera, Ph.D.
St. George's University of London

Title: "Use of Tissue Explants to Evaluate Mucosal Immune Response in NHP's and Humans"

Description: The HIV vaccine field is dependent upon testing in non-human primates (NHPs) as the only relevant model to study infection.  Read more >


Afam Okoye, Ph.D.
Vaccine & Gene Therapy Institute, Oregon Health & Science University

Title: "Role of Natural Killer cells in Antibody Mediated Protection
Following SHIV Challenge"

Description: Broadly neutralizing antibodies (Abs) are the "holy grail" of HIV/AIDS vaccine development, based on the concept that such Abs would bind directly to infectious viral particles, preventing their entry into susceptible target cells. Read more >


Lu-Ann Pozzi, Ph.D.
Harvard Medical School, New England Primate Research Center

Title: "An in vivo cytolytic CD8+ T lymphocyte assay for evaluating AIDS vaccine efficacy"

Description: Despite more than 20 years of research, the goal of developing a safe and effective HIV vaccine remains elusive. CD8+ cytotoxic T lymphocytes (CTL) are a critical component of antiviral immunity and will likely be an important determinant of protection mediated by an effective AIDS vaccine. Read more >


Wendy Yeh, Ph.D.
Beth Israel Deaconess Medical Center

Title: "HIV/SIV Mucosal Pathogenesis in the Male Genital Tract"

Description: Although the majority of the HIV-infected men worldwide acquired infection via the penile mucosa, little is known about the precise routes of viral entry into the male reproductive tract. Read more >

2010-2012 Scholars

Anne-Sophie Dugast, M.D.
Boston General Hospital and Ragon Institute

Title: "Impact of non-neutralizing antibodies on SHIV challenge"

Description: In addition to their capacity to neutralize the virus, antibodies display pleiotropic effects following the recruitment of innate immune cells expressing FcRs (Fc receptors) on their surface. Read more >


Katherine Bar, M.D.
University of Alabama Birmingham

Title: "Neutralization sensitivity of SIVsmE660 transmitted/founder viruses"

Project: A non-human primate (NHP) model that accurately predicts the immunogenicity of both T-cell and antibody-based vaccines candidates will hasten the development of a successful HIV vaccine. Read more >


Mohammed Asmal, M.D., Ph.D.
Beth Israel Deaconess Medical Center

Title: "Novel Transmitted Env SHIV for Investigating Mucosal Transmission in Rhesus"

Description: In order for an HIV vaccine to provide sterilizing immunity from mucosally acquired infection, the vaccine will need to target HIV-1 envelope. Read more >


James Kobie, Ph.D.
University of Rochester

Title: "Understanding the B cell Response to SIV/HIV in Non-Human Primates"

Description: Inducing a protective B cell response to HIV is clearly a major strategy for vaccine mediated eradication and possible therapy for HIV. Unfortunately, little is known about the HIV-specific humoral response outside of characterizing serum antibodies during infection or following vaccination. Read more >

2009-2011 Scholars

David Kaufman, M.D., Ph.D.
Beth Israel Deaconess Medical Center

Title: "Strategies to Improve the Breadth and Focus of Vaccine-Elicited CD8+ T-Lymphocyte Responses"

Description: A major challenge for HIV vaccine development is the enormous genetic diversity of the HIV virus—both at a population level and within each infected individual. Read more >


Shelby O'Connor, Ph.D.
University of Wisconsin

Title: "Defining the need for epitope-specific CD8 T cells in a successful HIV vaccine"

Description: The sequence of the proteins present in a successful HIV vaccine will naturally be different from transmitted viruses. Read more >


Sallie Permar, Ph.D.
Children's Hospital Boston

Title: "Vaccine-induction of HIV/SIV-specific, protective immune responses in breast milk"

Description: Breast milk transmission of HIV remains a major mode of HIV transmission from mother to child in the developing world, where formula feeding is associated with high morbidity and mortality. Read more >


Keith Reeves, Ph.D.
New England Primate Research Center

Title: "Role of Natural Killer Cells in Vaccine-Elicited Control of HIV/SIV Infections"

Description: Natural killer (NK) cells, as part of the innate immune response, are among the first cells to respond during HIV and SIV infections and are effective at killing virus-infected cells and inhibiting viral replication. Read more >


Lili Yang, Ph.D.
California Institute of Technology

Title: "Evaluation of a Dendritic Cell-Directed SIV Vaccine in Nonhuman Primates"

Description: My project aims to develop a new HIV vaccine, which interestingly, is based on a vector derived from HIV itself. By engineering the vector to target dendritic cells, the most powerful stimulator for human immune system, we hope to guide the immune system to fight HIV effectively. Read more >